Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial.

Spergel, J M; Boguniewicz, M; Paller, A S; Hebert, A A; Gallagher, P R; McCormick, C; Parneix-Spake, A; Hultsch, T

Spergel, J M; Boguniewicz, M; Paller, A S; Hebert, A A; Gallagher, P R; McCormick, C; Parneix-Spake, A; Hultsch, T.

Affiliation

Spergel JM; Division of Allergy and Immunology, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. Spergel@email.chop.edu

Br J Dermatol ; 157(2): 378-81, 2007 Aug.

Article in En | MEDLINE | ID: mdl-17573885

Subject(s)

Anti-Inflammatory Agents/therapeutic use; Dermatitis, Atopic/drug therapy; Dermatologic Agents/therapeutic use; Tacrolimus/analogs & derivatives; Administration, Cutaneous; Adolescent; Adult; Aged; Androstadienes/therapeutic use; Child; Child, Preschool; Double-Blind Method; Drug Therapy, Combination; Female; Fluticasone; Humans; Male; Middle Aged; Severity of Illness Index; Tacrolimus/therapeutic use; Treatment Outcome

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Tacrolimus / Dermatitis, Atopic / Dermatologic Agents / Anti-Inflammatory Agents Type of study: Clinical_trials Limits: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Male / Middle aged Language: En Journal: Br J Dermatol Year: 2007 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links